-
![1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine](/abs-image/US/2007/03/22/US20070066644A1/abs.jpg.150x150.jpg)
1.发明申请1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine 失效1 - [[1 - [（2-氨基-6-甲基-4-吡啶基）甲基] -4-氟-4-哌啶基]羰基] -4- [2-（2-吡啶基）-3H-咪唑并[4 ，5-b]吡啶-3-基]哌啶公开(公告)号：US20070066644A1
公开(公告)日：2007-03-22
申请号：US11523489
申请日：2006-09-19
IPC分类号： A61K31/4745 , C07D471/02
CPC分类号： C07D471/04
摘要： The present invention discloses the compound of Formula I and pharmaceutically acceptable salts and solvates thereof. The invention also relates to pharmaceutical compositions comprising the Compound of Formula I and its use in treating obesity, metabolic syndrome, diabetes, hepatic lipidosis or nonalcoholic fatty liver disease. The invention also relates to the use of a combination of the Compound of Formula I with additional therapeutic agents for treating obesity, metabolic syndrome, diabetes, hepatic lipidosis or nonalcoholic fatty liver disease.
摘要翻译： 本发明公开了式I化合物及其药学上可接受的盐和溶剂化物。 本发明还涉及包含式I化合物及其在治疗肥胖，代谢综合征，糖尿病，肝脏脂质沉积或非酒精性脂肪性肝病中的用途的药物组合物。 本发明还涉及式I化合物与用于治疗肥胖，代谢综合征，糖尿病，肝脏脂质沉积或非酒精性脂肪性肝病的其它治疗剂的组合的用途。
-
![1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine and Methods of Use Thereof](/abs-image/US/2008/03/06/US20080058370A1/abs.jpg.150x150.jpg)
2.发明申请1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine and Methods of Use Thereof 失效1 - [[1 - [（2-氨基-6-甲基-4-吡啶基）甲基] -4-氟-4-哌啶基]羰基] -4- [2-（2-吡啶基）-3H-咪唑并[4 ，5-b]吡啶-3-基]哌啶及其使用方法公开(公告)号：US20080058370A1
公开(公告)日：2008-03-06
申请号：US11837248
申请日：2007-08-10
IPC分类号： A61K31/437 , A61P1/00 , A61P3/00 , A61P3/04 , A61P3/10
CPC分类号： C07D471/04
摘要： The present invention discloses the compound of Formula I and pharmaceutically acceptable salts and solvates thereof. The invention also relates to pharmaceutical compositions comprising the Compound of Formula I and its use in treating obesity, metabolic syndrome, diabetes, hepatic lipidosis or nonalcoholic fatty liver disease. The invention also relates to the use of a combination of the Compound of Formula I with additional therapeutic agents for treating obesity, metabolic syndrome, diabetes, hepatic lipidosis or nonalcoholic fatty liver disease.
摘要翻译： 本发明公开了式I化合物及其药学上可接受的盐和溶剂化物。 本发明还涉及包含式I化合物及其在治疗肥胖，代谢综合征，糖尿病，肝脏脂质沉积或非酒精性脂肪性肝病中的用途的药物组合物。 本发明还涉及式I化合物与用于治疗肥胖，代谢综合征，糖尿病，肝脏脂质沉积或非酒精性脂肪性肝病的其它治疗剂的组合的用途。
-
搜索结果
2 条记录 (耗时 0.008 秒)
